MicroRNA 675 (miR-675)

MicroRNA 675 (miR-675) is a non-coding microRNA processed from the first exon of the long noncoding RNA H19[1][2][4]. It regulates gene expression post-transcriptionally by binding to target mRNAs, leading to their translational repression or degradation[2][3]. miR-675 has a context-dependent role in cancer: it can promote tumorigenesis by downregulating tumor suppressors like retinoblastoma protein (RB) in colorectal cancer, yet act as a tumor suppressor in prostate cancer and melanoma by inhibiting cell proliferation and invasion through targeting factors such as TGFBI and MTDH[1][6]. Beyond cancer, miR-675 is involved in developmental processes such as limiting placental growth by inhibiting IGF1R, and promoting skeletal muscle differentiation and regeneration predominantly by targeting SMAD transcription factors[2][4][5]. Its expression is tightly regulated, notably by RNA-binding proteins such as HuR, and it displays altered expression in disease states including osteoarthritis and muscle regeneration disorders[5][2]. Clinically, miR-675 is considered a biomarker for several cancers and musculoskeletal pathologies, and therapeutic strategies manipulating its levels are under research[1][6][4][7].

Other names

hsa-mir-675MIR675MIRN675hsa-mir-675-3phsa-mir-675-5p

Not applicable in direct drug targeting (miRNAs themselves are not typically bound by conventional small-molecule drugs); however, oligonucleotide-based therapies targeting or mimicking miR-675 may act by restoring or inhibiting its gene regulatory functions.